UNRESECTABLE DIGESTIVE SYSTEM NEUROENDOCRINE TUMOR G2
Clinical trials for UNRESECTABLE DIGESTIVE SYSTEM NEUROENDOCRINE TUMOR G2 explained in plain language.
Never miss a new study
Get alerted when new UNRESECTABLE DIGESTIVE SYSTEM NEUROENDOCRINE TUMOR G2 trials appear
Sign up with your email to follow new studies for UNRESECTABLE DIGESTIVE SYSTEM NEUROENDOCRINE TUMOR G2, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Double radiation attack tested on hard-to-treat gut tumors
Disease control Recruiting nowThis early-phase trial tests whether adding a precise external radiation treatment (SBRT) before a standard radioactive drug therapy (177Lu-DOTATATE) is safe and works better for people with large, inoperable digestive neuroendocrine tumors. About 15 adults whose tumors have grow…
Matched conditions: UNRESECTABLE DIGESTIVE SYSTEM NEUROENDOCRINE TUMOR G2
Phase: PHASE1 • Sponsor: Emory University • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
Second dose of targeted radiation may outperform standard drugs in advanced gut tumors
Disease control Recruiting nowThis study tests whether a second round of a targeted radiation therapy (177Lu-DOTATATE) works better than standard drugs (everolimus, sunitinib, or cabozantinib) for people with advanced gastroenteropancreatic neuroendocrine tumors (GEPNETs) that have spread or can't be removed.…
Matched conditions: UNRESECTABLE DIGESTIVE SYSTEM NEUROENDOCRINE TUMOR G2
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:54 UTC